Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

News about Vertex Pharmaceuticals Inc., including commentary and archival articles published in The New York Times.

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, causing the company’s shares to fall.

Vertex Pharmaceuticals Inc. said more than 20,000 prescriptions have been dispensed for its new non-addictive painkiller, a sign that the drug is gaining some early traction as it attempts to ...

Vertex Pharmaceuticals Inc. said it's stopping work on two potential drugs for a genetic lung disorder, but is now predicting a better-than-expected 2024 product revenue. The Boston drug developer ...

If you have non-public information about Vertex Pharmaceuticals Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange ...

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.

Vertex Pharmaceuticals Inc. ( (VRTX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented to its investors.

Jefferies upgrades Vertex Pharmaceuticals to Buy, highlighting a promising pipeline and $5 billion-$7 billion growth potential from pain and kidney treatments.